RHHBYRHHBY
ImmunologyOncology80 cited findings · profile updated 2026-08-25
58.47 USDnot live — refreshed daily
About RHHBY
RHHBY is active in oncology research, with clinical trials investigating various treatments. In the OCARINA I trial, 80.3% of patients in the 1200 mg dose group experienced Grade 1 or 2 AEs, while 23.7% of patients receiving OCR SC 920 or 1200 mg experienced AEs of grade 3. Infections were also observed, with 8.8% of patients in the ocrelizumab 1200 mg SC group experiencing Grade 3 infection, and 0.8% experiencing Grade 5 infection. Specific Grade 3 infections included COVID-19 (4.0%), pneumonia (2.4%), COVID-19 pneumonia (0.8%), encephalitis (0.8%), and SARS-CoV-2 sepsis (0.8%).
In the OCARINA II trial, infusion-related reactions (IRRs) were noted, with an incidence of 16.1% at Day 1 infusion and 6.0% at Day 14 infusion. Among patients treated for IRRs, 45.0% experienced Grade 1 severity IRRs and 55.0% experienced Grade 2 severity IRRs. Common IRR symptoms included pruritus (3.4%), headache (2.5%), throat irritation (1.7%), tachycardia (1.7%), and erythema (1.7%). In the OCARINA II Controlled Period, 5.9% of patients in the OCR IV arm experienced AEs of Grade 3, and 3.4% in the OCR SC arm. Serious AEs of grade ≥ 3 were observed in 5.9% of the OCR IV arm and 3.4% of the OCR SC arm. In the OCARINA II All Exposure analysis, 2.2% of patients in the OCR SC group experienced AEs of Grade 3.
Glofitamab, another drug in development, showed a high incidence of Cytokine Release Syndrome (CRS) AEs, with 66.1% (ASTCT 2019) and 64.3% (ASTCT 2019) of patients experiencing CRS of any grade. Grade ≥ 2 CRS AEs were observed in 16.2% of patients (ASTCT 2019). Other adverse events with glofitamab included Grade ≥ 2 neurological AEs (14.3%), Grade ≥ 2 ALT, AST, or total bilirubin elevation (7.1%), and Grade ≥ 3 febrile neutropenia (2.6%). Tumour flare of any grade was reported in 11.0% of patients, with 7.1% experiencing Grade ≥ 2 tumour flare. In the POPLAR study, atezolizumab showed treatment-related Grade 3 or 4 AEs in 11.3% of patients, compared to 38.6% for docetaxel. Grade 5 AEs were 4.2% for atezolizumab and 3.7% for docetaxel, with treatment-related Grade 5 AEs at 0.7% for atezolizumab and 2.2% for docetaxel.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Grade 3 infection in ocrelizumab 1200 mg SC group | 8.8 % | Roche Holding AG — Ocrevus EMA EPAR variation assessment report (EMEA/, p.72 |
| Incidence of IRRs at Day 1 infusion (OCARINA II) | 16.1 % | Roche Holding AG — Ocrevus EMA EPAR variation assessment report (EMEA/, p.72 |
| CRS AEs of any grade (ASTCT 2019) for glofitamab | 66.1 % | Roche Holding AG — Columvi EMA EPAR public assessment report (EMEA/H/C, p.114 |
| treatment-related Grade 3 or 4 AEs (atezolizumab) vs (docetaxel) | 11.3 % vs 38.6 % | Roche Holding AG — Tecentriq EMA EPAR public assessment report (EMEA/H, p.166 |
| Grade ≥ 2 neurological AE (glofitamab) | 14.3 % | Roche Holding AG — Columvi EMA EPAR public assessment report (EMEA/H/C, p.141 |
| Grade ≥3 AEs (ALINA study) | 30 % | HOFFMANN-LA ROCHE — Alecensa FDA Review (NDA/BLA 208434, 2024), p.80 |
Key projects
- Ocrevus (multiple sclerosis) — null
In OCARINA I, 80.3% of patients in the 1200mg dose experienced AEs of Grade 1 or 2.
- glofitamab (oncology) — null
CRS AEs of any grade (ASTCT 2019) were observed in 66.1% of patients treated with glofitamab.
- atezolizumab (non-small cell lung cancer) — null
In the POPLAR study, treatment-related Grade 3 or 4 AEs for atezolizumab were 11.3%.
- Avastin (oncology) — null
In the Young Patient Cohort, Grade 3 AEs were observed in 2 patients.
- Alecensa (oncology) — null
In the ALINA study, Grade ≥3 AEs incidence was 30%.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Immunology research library →